Summary of Arcus Therapeutics Conference Call Company and Industry Overview - **Company**: Arcus Therapeutics - **Industry**: Oncology, specifically focusing on HIF-2 inhibitors for cancer treatment Key Points and Arguments Casdatifan vs. Belzutifan - **Differentiation**: Casdatifan is positioned as a best-in-class HIF-2 inhibitor compared to Merck's belzutifan, primarily due to its pharmacokinetic and pharmacodynamic (PK/PD) profile, which allows for more effective targeting of the cancer [2][6] - **Clinical Efficacy**: In late-line settings, casdatifan shows a primary progression rate of approximately 18% compared to belzutifan's nearly 35% [3] - **Response Rates**: The confirmed response rate for casdatifan is about 35% across 120 patients, with the 100 mg cohort showing a 45% response rate, significantly higher than belzutifan's over 20% [4] - **Progression-Free Survival (PFS)**: Median PFS for casdatifan is reported at 12.2 months, with the 100 mg cohort exceeding 15 months, while belzutifan shows around 5.6 months [4] Biomarker Data - **Erythropoietin Suppression**: Casdatifan demonstrates deeper and more durable suppression of erythropoietin production compared to belzutifan, which loses its pharmacodynamic effect after about 9 weeks [5] - **Correlation with Efficacy**: There is a clear correlation between the ability to suppress erythropoietin and clinical outcomes, reinforcing the efficacy of casdatifan [5] Treatment Durability - **Prolonged Disease Control**: Patients on casdatifan can experience prolonged disease control, with some remaining stable for over two years, indicating a non-toxic mechanism that allows the immune system to strengthen [10][11] - **Resistance Mechanism**: There is no known mechanism for resistance to HIF-2 inhibitors, which is a significant advantage over other cancer therapies [12] Clinical Development and Future Studies - **ARC-20 Study**: The study has added multiple cohorts to evaluate different dosing regimens and combinations, with a steady stream of data expected over the next two to three years [25] - **Upcoming Data**: Key datasets expected include the combination of casdatifan with cabozantinib and anti-PD-1 therapies, with initial results anticipated between July and October [26][30] Market Position and Strategy - **TKI Partner Selection**: Cabozantinib was chosen as the TKI partner due to its familiarity and better tolerability among clinicians compared to lenvatinib, which has more complex dosing [32][34] - **Regulatory Strategy**: The primary endpoint for the PEAK-1 study is PFS, which aligns with regulatory standards for second-line RCC treatments, and is expected to maximize the probability of success [43][44] Competitive Landscape - **Market Dynamics**: The use of HIF-2 inhibitors is expected to expand across multiple lines of therapy, potentially leading to a larger market opportunity compared to other tumor types where treatment options are limited [69] Additional Important Insights - **Anemia Management**: Anemia rates for casdatifan are comparable to belzutifan, with ongoing improvements in managing these side effects expected as clinical experience grows [21][23] - **Subsequent Therapy Considerations**: The geographic footprint for belzutifan usage is limited outside the U.S., which may not significantly impact the subsequent therapy landscape for casdatifan [53] This summary encapsulates the critical insights from the conference call regarding Arcus Therapeutics' strategic positioning, clinical data, and future outlook in the oncology market.

Core Insights - Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on innovative cancer therapies, competing with firms like Replimune Group, Mersana Therapeutics, Arvinas, Denali Therapeutics, and Syndax Pharmaceuticals [1] Financial Metrics - Arcus has a Weighted Average Cost of Capital (WACC) of 8.04% and a Return on Invested Capital (ROIC) of -42.51%, resulting in a ROIC to WACC ratio of -5.29, indicating it is not generating returns above its cost of capital [2] - Replimune Group has a WACC of 7.66% and a ROIC of -113.17%, leading to a ROIC to WACC ratio of -14.78, suggesting it is further from achieving returns above its cost of capital compared to Arcus [3] - Mersana Therapeutics has a WACC of 7.09% and a ROIC of -280.70%, resulting in a ROIC to WACC ratio of -39.57, indicating a more challenging financial position [3] - Arvinas stands out with a WACC of 12.77% and a ROIC of -20.02%, giving it the highest ROIC to WACC ratio of -1.57, suggesting potential for improvement compared to its peers [4] - Denali Therapeutics and Syndax Pharmaceuticals face negative ROIC to WACC ratios of -5.99 and -10.30, respectively, highlighting the common struggle among clinical-stage biopharmaceutical companies to generate returns above their cost of capital [5]

Group 1 - The article emphasizes the importance of combining scientific expertise with financial analysis in the biotechnology sector to identify promising companies and investment opportunities [1] - The focus is on biotechnology companies that are innovating through unique mechanisms of action, first-in-class therapies, or platform technologies that could reshape treatment paradigms [1] - The analysis will cover companies at various stages of development, from early clinical pipelines to commercial-stage biotechs, evaluating the science behind drug candidates and the competitive landscape [1] Group 2 - The goal is to provide insights that help investors understand both the opportunities and risks in the biotech sector, where breakthrough science can lead to significant returns [1] - The approach includes careful scrutiny of clinical trial design and potential market opportunities while balancing financial fundamentals and valuation [1]

Core Insights - The article emphasizes the importance of combining scientific expertise with financial analysis in the biotechnology sector to identify promising investment opportunities [1]. Group 1: Industry Focus - The biotechnology sector is characterized by innovation through unique mechanisms of action, first-in-class therapies, and platform technologies that can reshape treatment paradigms [1]. - Breakthrough science in biotechnology has the potential to yield outsized returns for investors, but it also requires careful scrutiny due to inherent risks [1]. Group 2: Analytical Approach - The analysis will cover biotechnology companies at various stages of development, from early clinical pipelines to commercial-stage biotechs [1]. - Key evaluation criteria include the science behind drug candidates, competitive landscape, clinical trial design, and potential market opportunities, alongside financial fundamentals and valuation [1].

Core Insights - Arcus Biosciences aims to establish casdatifan as a "best-in-class" HIF-2α inhibitor for clear cell renal cell carcinoma (ccRCC) with updated clinical data showing promising efficacy compared to belzutifan [3][5][14] Clinical Data and Development - Updated analysis from the ARC-20 study indicates a median progression-free survival (PFS) of 15.1 months for casdatifan monotherapy, significantly longer than the 5.6-month PFS reported for belzutifan in similar late-line settings [1][2][5] - The confirmed overall response rate (ORR) for casdatifan has risen to 45% in the latest data [5] - The Phase III PEAK-1 trial is actively enrolling patients, comparing casdatifan plus cabozantinib against cabozantinib alone, with a goal to complete enrollment by year-end [6][10] Financial Overview - Arcus ended Q4 with $1.0 billion in cash, following a $288 million financing, and expects to fund operations into at least the second half of 2028 [4][17][18] - The company projects 2026 GAAP revenue between $45 million and $55 million, with anticipated decreases in operating expenses [18] Market Opportunity - The renal cell carcinoma (RCC) market is projected to exceed $10 billion annually, with expectations to grow to $13 billion by 2030, positioning casdatifan as a key player in this competitive landscape [14][15] - Arcus estimates peak sales for casdatifan could reach $2.5 billion in the IO-experienced setting and $3 billion or more in the first-line setting [15] Immunology Pipeline - Arcus is developing an inflammation and immunology (I&I) portfolio, with plans to enter clinical trials for a MRGPRX2 antagonist and a selective TNF receptor 1 inhibitor [16]

Financial Data and Key Metrics Changes - The company reported GAAP revenue of $33 million for Q4 2025, an increase from $26 million in Q3 2025, primarily driven by collaboration with Gilead [35] - Cash at the end of Q4 was $1 billion, up from $841 million at the end of Q3, bolstered by a $288 million financing in November [35][36] - R&D expenses decreased to $121 million in Q4 from $141 million in Q3, while G&A expenses slightly decreased from $27 million to $26 million [35] Business Line Data and Key Metrics Changes - The confirmed overall response rate (ORR) for the 100 mg cohort of casdatifan increased from 35% to 45%, with a median progression-free survival (PFS) of 15.1 months [16][18] - The pooled analysis ORR improved from 31% to 35%, significantly higher than belzutifan's observed rates [16][18] Market Data and Key Metrics Changes - The renal cell carcinoma (RCC) market is projected to grow from over $10 billion annually today to $13 billion by 2030, with casdatifan targeting a peak sales opportunity of $5 billion in first and second-line RCC settings [24][26] - The company aims to capture a substantial share of the IO-experienced setting, which includes approximately 21,000 patients in major markets, nearly double the third-line patient population where belzutifan is approved [26] Company Strategy and Development Direction - The company is focused on establishing casdatifan as the best-in-class HIF-2 inhibitor and the new standard of care for clear cell RCC, with a fast-to-market strategy for its Phase III study, PEAK-1 [4][8] - A TKI-free regimen is being developed for frontline therapy, which is expected to improve patient quality of life and treatment outcomes [10][11] - The immunology portfolio is also being expanded, with two programs expected to enter the clinic within the next 12 months [14][30] Management's Comments on Operating Environment and Future Outlook - Management emphasized the transformative potential of 2026 for the company, with multiple data presentations and advancements in clinical programs expected [4][39] - The company is confident in its ability to fund operations until at least the second half of 2028, with a significant decrease in operating expenses anticipated for 2026 [37][38] Other Important Information - The company is leveraging its ARC-20 study to drive development strategy for casdatifan, with a focus on demonstrating its best-in-class profile [12][22] - The upcoming ASCO GU presentation is expected to provide critical data that will reinforce the differentiation of casdatifan from belzutifan [7][39] Q&A Session Summary Question: What are the benchmarks for IO therapies as the company moves away from TKI-based regimens? - Management highlighted Ipi-Nivo as a key benchmark, noting its primary progression rate of 20%-25% and PFS of around 12 months, with the goal to demonstrate meaningful improvement with casdatifan [44][46] Question: What is the status of the volrustomig plus casdatifan study? - The study was paused but continues to provide valuable data, with no primary progression observed since dose adjustments [50][51] Question: How does the company view the upcoming LITESPARK-011 data from Merck? - Management expressed optimism that positive data from Merck would validate the field and drive enrollment for PEAK-1, with confidence in outperforming Merck's combination [65][66] Question: What is the impact of potential discontinuation of STAR-121 based on futility analysis? - Management indicated minimal operational impact as the study is fully enrolled, with a decrease in expenses expected in the latter stages of the trial [81][82]

Financial Data and Key Metrics Changes - The company reported GAAP revenue of $33 million for Q4 2025, an increase from $26 million in Q3 2025, primarily driven by collaboration with Gilead [35] - R&D expenses decreased to $121 million in Q4 2025 from $141 million in Q3 2025, while G&A expenses slightly decreased from $27 million to $26 million [35] - The cash position improved to $1 billion at the end of Q4 2025, up from $841 million at the end of Q3 2025, bolstered by a $288 million financing in November [35] Business Line Data and Key Metrics Changes - The confirmed overall response rate (ORR) for the 100 mg cohort of casdatifan increased from 35% to 45%, indicating significant efficacy improvement [16] - The median progression-free survival (PFS) for the 100 mg cohort was reported at 15.1 months, with a follow-up of 17.8 months, showcasing a strong performance compared to belzutifan [16][18] - The pooled analysis of casdatifan showed an ORR increase from 31% to 35%, further establishing its efficacy over belzutifan [16] Market Data and Key Metrics Changes - The renal cell carcinoma (RCC) market is projected to grow from over $10 billion annually today to $13 billion by 2030, with casdatifan targeting both late-line and early-line settings [24] - The company estimates a peak sales opportunity of $2.5 billion in the IO-experienced setting and potentially $3 billion or more in the first-line setting, indicating a substantial market opportunity [26] Company Strategy and Development Direction - The company aims to establish casdatifan as the best-in-class HIF-2 inhibitor and the new standard of care for clear cell RCC, focusing on a TKI-free regimen [4][8] - The first phase 3 study, PEAK-1, is actively enrolling and designed to establish casdatifan plus cabozantinib as the new standard of care in IO-experienced RCC [19] - The company is also exploring its immunology portfolio, with plans to advance two lead programs into the clinic by early next year [30] Management's Comments on Operating Environment and Future Outlook - Management emphasized that 2026 will be transformative for the company, with multiple data presentations and advancements in clinical programs expected [4] - The management expressed confidence in the differentiation of casdatifan compared to belzutifan, particularly in terms of safety and efficacy [7][8] - The company anticipates that the results from the upcoming ASCO GU presentations will validate their ongoing studies and drive enrollment in PEAK-1 [66] Other Important Information - The company plans to initiate a phase 3 study for casdatifan in the frontline setting by the end of 2026, contingent on safety and efficacy data [22] - The company owns nearly all rights to casdatifan, with revenues expected to accrue primarily to them, enhancing their financial outlook [27] Q&A Session Summary Question: What are the benchmarks for IO therapies as the company moves away from TKI-based regimens? - Management highlighted ipilimumab-nivolumab (ipi-nivo) as a key benchmark, noting its primary progression rate of 20%-25% and PFS of around 12 months [44] Question: What is the status of the volrustomig plus casdatifan study? - The study was paused but continues to provide valuable data, with no primary progression observed since dose adjustments [50] Question: How does the company view the upcoming LITESPARK-011 data from Merck? - Management expects positive data from LITESPARK-011 to validate the field and drive enrollment in their own studies, believing they can outperform Merck's combination [66]

Financial Data and Key Metrics Changes - The company reported GAAP revenue of $33 million for Q4 2025, an increase from $26 million in Q3 2025, primarily driven by collaboration with Gilead [34] - Cash at the end of Q4 was $1 billion, up from $841 million at the end of Q3, bolstered by a $288 million financing in November [34] - R&D expenses decreased to $121 million in Q4 from $141 million in Q3, while G&A expenses slightly decreased from $27 million to $26 million [34] Business Line Data and Key Metrics Changes - The confirmed overall response rate (ORR) for the 100 mg cohort of casdatifan increased from 35% to 45%, which is twice that observed with belzutifan [15] - The median progression-free survival (PFS) for the 100 mg cohort was reported at 15.1 months, significantly longer than the 5.6 months observed for belzutifan [16][17] Market Data and Key Metrics Changes - The renal cell carcinoma (RCC) market is projected to grow from over $10 billion annually today to $13 billion by 2030, with casdatifan targeting a peak sales opportunity of $5 billion in first and second-line RCC alone [22][25] - The company aims to capture a substantial share of the IO-experienced setting, which includes approximately 21,000 patients in major markets, nearly double the third-line patient population where belzutifan is currently approved [25] Company Strategy and Development Direction - The company is focused on establishing casdatifan as the best-in-class HIF-2 inhibitor and the new standard of care for clear cell renal cell carcinoma [4] - A fast-to-market strategy is being employed with the PEAK-1 study, which is actively enrolling and designed to establish CAS plus cabozantinib as the new standard of care in IO-experienced clear cell RCC [18] - The company is also developing a TKI-free regimen for frontline therapy, which is expected to improve patient quality of life and treatment outcomes [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized that 2026 will be a transformative year for the company, with significant data presentations and advancements in the clinical program for casdatifan [4] - The management expressed confidence in the differentiation of casdatifan compared to belzutifan, particularly regarding safety and efficacy profiles [6][10] Other Important Information - The company plans to initiate a phase 3 study for casdatifan in the frontline setting by the end of 2026, contingent on safety and efficacy data [20] - The immunology portfolio is also being developed, with two programs expected to enter the clinic over the next 12 months [28] Q&A Session Summary Question: What trials are being looked at for IO benchmarks as the company moves away from TKI-based regimens? - Management indicated that ipilimumab-nivolumab (ipi-nivo) is a key focus, with a primary progression rate of 20%-25% and a PFS of around 12 months serving as benchmarks for improvement [42][43] Question: What is the status of the volrustomig plus casdatifan study? - The study was paused but continues to provide valuable data, with no primary progression observed since dose adjustments [49][50] Question: How do deeper EPO reductions correlate with responses in biomarker analyses? - There is a soft correlation between higher baseline EPO levels and the extent of reduction, indicating stronger HIF-2 activity in tumors [54][56] Question: What are the expectations for the LITESPARK-011 study? - Management expects good data from Merck's study, which will validate the field and potentially drive enrollment for the PEAK-1 study [64][65]

Full Year 2025 Investor Presentation Oncology and Immunology Portfolio Summary February 25, 2026 Forward-looking Statements/Safe Harbor Forward-Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not historical facts are forward-looking statements, including, without l ...

Financial Performance - Total revenues for 2025 decreased to $247 million, a 4% decline from $258 million in 2024, primarily due to lower revenue from collaborations with Taiho and Gilead [398]. - The net loss for 2025 was $353 million, a 25% increase compared to a net loss of $283 million in 2024 [397]. - Non-operating income decreased to $33 million in 2025, a 31% decline from $48 million in 2024, primarily due to lower interest income [408]. - Cash used in operating activities was $482 million in 2025, significantly higher than $170 million in 2024, largely due to increased R&D expenditures [420]. - Total operating expenses for 2025 were $633 million, an 8% increase from $588 million in 2024 [397]. Research and Development - The median progression-free survival (mPFS) for the pooled analysis of the HIF-2α inhibitor casdatifan was 12.2 months, with a 15.2 months median follow-up [373]. - The confirmed overall response rate for casdatifan plus cabozantinib in metastatic cancer patients was 46% [373]. - The company plans to decrease R&D expenses in the near term as it winds down studies for domvanalimab, while increasing investment in casdatifan and inflammation programs [391]. - The Phase 3 STAR-221 study was discontinued due to futility, as the domvanalimab-based combination did not improve overall survival compared to nivolumab plus chemotherapy [380]. - The company completed enrollment of the PRISM-1 trial within 12 months of initiation, evaluating quemliclustat in pancreatic cancer [380]. - The company expects to incur substantial expenditures for the development and potential commercialization of investigational products and ongoing R&D programs [384]. Cash and Financing - As of December 31, 2025, the company had $1.0 billion in cash, cash equivalents, and marketable securities, expected to fund operations until at least the second half of 2028 [385]. - In 2025, the company raised approximately $438 million through two underwritten offerings of common stock [417]. - The company has outstanding long-term debt with a carrying value of $99 million as of December 31, 2025, compared to $48 million in 2024 [445]. - Cash provided by financing activities for 2023 includes net proceeds of $25 million from common stock issuance and $8 million from equity award plans [427]. - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $1.0 billion, up from $992 million in 2024 [444]. Collaboration and Revenue Recognition - The company received $37 million in collaboration payments in 2025, a significant decrease from $232 million in 2024 [420]. - The company recognized a cumulative catch-up to revenue of $143 million due to a contract modification related to the Gilead collaboration [436]. - At December 31, 2025, the company had $37 million in deferred revenue related to R&D programs that are satisfied over time [439]. - A hypothetical 5% increase in the total estimated effort required to satisfy performance obligations could increase related revenue recognized by $28 million [440]. - The company is contractually obligated to make significant payments upon achieving various development, regulatory, and commercial milestones [429]. Market Risks - The company is exposed to market risks from changes in interest rates and foreign currency exchange rates [443]. - A hypothetical 100 basis point increase in interest rates would not materially affect the fair market value of cash, cash equivalents, and marketable securities [444]. - A hypothetical 20% adverse movement in foreign currency exchange rates would not result in a material impact on the company's financial position or income [446]. Shareholder Information - Gilead holds approximately 25.1% of the company's outstanding common stock as of December 31, 2025 [379].